Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, showing a favorable safety and efficacy profile compared to placebo [1][2][3] Efficacy Data - In Cohort 1, 26% of patients receiving soquelitinib achieved IGA 0 or 1, and 37% achieved EASI 75, while none in the placebo group reached these endpoints after four weeks [3][4] - The trial included 16 patients in Cohort 1 and 10 patients in Cohort 2, with the latter showing improved results with a 200 mg once daily dose compared to the initial cohort [2][3] Safety Profile - No significant safety issues or clinically significant laboratory abnormalities were reported, with all patients in Cohort 2 completing the 28-day treatment [4] Trial Design - The Phase 1 trial is randomized, double-blind, and placebo-controlled, planned to enroll 64 patients with moderate to severe atopic dermatitis who have failed prior therapies [7] - The trial examines multiple dosing regimens, including 100 mg twice daily and 200 mg once daily, with a total of four cohorts [7][8] Future Outlook - The company plans to report full results from all cohorts in the second quarter of 2025 and is also advancing a Phase 3 trial for relapsed peripheral T cell lymphoma [2][4]

Core Viewpoint - Corvus Pharmaceuticals, Inc. will present a corporate overview and conduct one-on-one meetings with investors at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025 [1]. Group 1: Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [3]. - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus is developing other clinical-stage candidates targeting a range of cancer indications [3]. Group 2: Event Details - Richard A. Miller, M.D., the president and CEO of Corvus Pharmaceuticals, will present on January 15 at 2:15 pm ET / 11:15 am PT [1]. - An audio webcast of the presentation will be available live and for 30 days post-event, accessible via the investor relations section of the Corvus website [2].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m. PT BURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today anno ...

Core Insights - Corvus Pharmaceuticals will announce interim data from a Phase 1 clinical trial of soquelitinib for atopic dermatitis on December 18, 2024 [1] - A conference call and webcast will be held to discuss the clinical data, accessible via phone and the company's website [2] About Soquelitinib - Soquelitinib is an investigational oral small molecule drug that selectively inhibits ITK, impacting T cell differentiation and immune function [3] - The drug has shown potential in treating cancers and autoimmune diseases by shifting T cell differentiation towards regulatory cells [3] - A registrational Phase 3 trial for relapsed peripheral T cell lymphoma has been initiated based on positive Phase 1/1b results [3] About Corvus Pharmaceuticals - Corvus Pharmaceuticals is focused on developing ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [4] - The company’s lead candidate is soquelitinib, with other clinical-stage candidates targeting different cancer indications [4]

BURLINGAME, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, as a novel approach to modulate tumor immunity. The data was published in npj Drug Discovery (part of the Nature portfolio of journals), an open access, international, peer-reviewed journal dedicated to publishing the highest quali ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases Data will be presented in a poster at ACR Convergence 2024, the annual meeting of the American College of Rheumatology BURLINGAME, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data highlighting the potential of soquelitinib, the Company’s lea ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are putting Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS ) in the spotlight. As you can see, the shares of this clinical stage biopharmaceutical company have soared in rece ...

Financial Data and Key Metrics Changes - Research and development expenses increased to $5.2 million in Q3 2024 from $4 million in Q3 2023, primarily due to higher clinical trial expenses for soquelitinib [7] - The net loss for Q3 2024 was $40.2 million, significantly higher than the net loss of $6 million in Q3 2023, which included a noncash loss from Angel Pharmaceuticals [7] - Cash, cash equivalents, and marketable securities totaled $41.7 million as of September 30, 2024, compared to $27.1 million at the end of 2023 [8] - The company anticipates that its cash runway extends into 2026, aided by the early exercise of common stock warrants [9] Business Line Data and Key Metrics Changes - Soquelitinib is advancing in multiple clinical trials, including a Phase III trial for peripheral T-cell lymphoma (PTCL) and a Phase I trial for atopic dermatitis [10][19] - The Phase I trial for atopic dermatitis is designed to enroll 64 patients, with the first cohort already completed and the second cohort currently enrolling [12][14] - The objective response rate for the Phase III PTCL trial remains at 39%, with a median progression-free survival (PFS) of 6.2 months [22] Market Data and Key Metrics Changes - The FDA has granted orphan drug designation and Fast Track designation for soquelitinib for the treatment of relapsed T-cell lymphoma [19] - The company is enrolling patients at multiple clinical sites for the PTCL trial, aiming for 40 to 50 centers across the U.S., Australia, Canada, and South Korea [20] Company Strategy and Development Direction - The company is focusing on advancing soquelitinib for both oncology and autoimmune diseases, with plans to initiate a solid tumor trial in early 2025 [23][28] - There is a strong emphasis on the potential of soquelitinib in treating a broad range of immune diseases and cancers, supported by preclinical data [18] - The company is also developing second- and third-generation ITK inhibitors targeting various immunology indications, including asthma and inflammatory bowel disease [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress of the atopic dermatitis trial and the potential advantages of soquelitinib, including its oral administration and safety profile [18] - The company plans to present complete data from the atopic dermatitis trial in December and anticipates further data in early 2025 [28] - Management highlighted the importance of the upcoming clinical milestones and the potential for ITK inhibition in immunology and cancer [29] Other Important Information - The company is actively monitoring patients in ongoing trials and has reported sustained responses in several patients [21] - The mechanism of action of soquelitinib is believed to induce an immune response that can handle a broad spectrum of tumors, potentially reducing the emergence of resistance [46] Q&A Session Summary Question: Can you comment on the kinetics of ITK inhibition on clinical scores in atopic dermatitis? - Management noted that improvements are observed within the first week, with expectations for durable effects based on the drug's mechanism of action [32] Question: What is the follow-up time period for the cohorts in the atopic dermatitis trial? - Management confirmed that 28-day data will be reported in December, with complete follow-up for Cohort 1 and partial follow-up for Cohort 2 [36] Question: What is the typical prior therapy for patients enrolled in the atopic dermatitis trial? - Most patients have failed topical therapies, with some not having failed systemic therapies yet [42] Question: How does the company plan to differentiate dosing between oncology and autoimmune diseases? - Management indicated that continuous treatment may not be necessary for atopic dermatitis, unlike cancer treatments [52] Question: What are the criteria for success in the Phase III PTCL trial? - The statistical plan aims for a 1.5-month improvement in PFS over the control arm, with a hazard ratio of about 0.56 [61]